Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Masitinib
Introduction
{{Drugbox | drug_name = | IUPAC_name = 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide | image = Masitinib Wiki str.png
| alt = | caption =
| tradename = Masivet, Kinavet | Drugs.com = International Drug Names | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
| CAS_number = 790299-79-5 | ATCvet = | ATC_prefix = L01 | ATC_suffix = XE22 | ATC_supplemental = | PubChem = 10074640 | ChEMBL = 1908391 | ChemSpiderID = 8250179 | DrugBank =
| C=28 | H=30 | N=6 | O=1 | S=1 | molecular_weight = 498.64 g/mol | smiles = O=C(c1ccc(cc1)CN2CCN(C)CC2)Nc3cc(c(cc3)C)Nc4nc(cs4)c5cccnc5 | StdInChI = InChI=1S/C28H30N6OSc1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32) | StdInChIKey = WJEOLQLKVOPQFV-UHFFFAOYSA-N }}
Overview
Overview
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs.[1][2] Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
Masitinib is being studied for several human conditions including cancers. It is used in Europe to fight orphan diseases.[3]
Mechanism of action
Mechanism of action
Masitinib inhibits the receptor tyrosine kinase c-Kit which is displayed by various types of tumour.[2] It also inhibits the platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR).
References
References
- ↑ Hahn, K.A.; Oglivie, G.; Rusk, T.; Devauchelle, P.; Leblanc, A.; Legendre, A.; Powers, B.; Leventhal, P.S.; Kinet, J.-P.; Palmerini, F.; Dubreuil, P.; Moussy, A.; Hermine, O. (2008). “Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors”. Journal of Veterinary Internal Medicine. 22 (6): 1301–1309. doi:10.1111/j.1939-1676.2008.0190.x. ISSN 0891-6640.
- ↑ 2.0 2.1 Information about Masivet at the European pharmacy agency website
- ↑ Orphan designation for Masitinib at the European pharmacy agency website
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]